Ultragenyx Pharma (RARE) PT Raised to $68 at Jefferies; Reiterates Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ultragenyx Pharma (RARE) PT Lowered to $79 at Morgan Stanley
May 8, 2017 9:08 AM EDTMorgan Stanley lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $79.00 (from $84.00) while maintaining a Equalweight rating.
... MoreUltragenyx Pharma (RARE) Tops Q1 EPS by 8c
May 4, 2017 4:46 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.63), $0.08 better than the analyst estimate of ($1.71).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More